| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format
KELOWNA, BC / ACCESSWIRE / September 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that approval has been received from an independent review board, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) tirzepatide in an oral dose format.
Subject recruitment will begin shortly and the Company will announce as soon as the first dosing has begun, currently expected in late October. Lexaria anticipates the final doses in the study to be administered in late November.
The Study will be conducted in up to 10 healthy volunteers and will study a single injected dose of Zepbound® (tirzepatide) monitored over a 7-day duration, compared to 7 consecutive days of daily oral dosing of DehydraTECH-processed Zepbound®.
Tirzepatide is currently approved for use in the USA under the brand names Zepbound® and Mounjaro,® owned by Eli Lilly™. These two brands combined are expected to generate approximately $15 billion in revenue in 2024.
Tolerability (side effects), blood absorption levels (pharmacokinetics or "PK"), and blood sugar control will all be evaluated in this Study. The DehydraTECH compositions for this Study will be compound-formulated using commercially available Zepbound® injectable formulation as the tirzepatide input material.
In two previous human pilot studies, Lexaria has evidenced that processing of semaglutide (sold by Novo Nordisk® under the brands Rybelsus®, Ozempic®, and Wegovy®) with DehydraTECH and administered in an oral format, shows improvements in absorption rates and a reduction in both blood sugar and in adverse events, as compared to the Rybelsus® tablet. In pilot Study #3 referred to today, Lexaria is hopeful of evidencing meaningful absorption rates of tirzepatide in a swallowed oral format, which is not available in the market today since it is currently administered only by injection.
In a separate development, Lexaria also announces that the contract research organization ("CRO") hired by Lexaria to perform the Company's 12-week study GLP-1-H24-4 that will evaluate various DehydraTECH-GLP-1 formulations and other treatments, has submitted the required package of information for its own Human Research Ethics Committee review. This study, expected to be regarded as a Phase 1b registrational study by the U.S. Food and Drug Administration, is expected to begin first-in-patient dosing this winter, in Australia. Lexaria will provide an update once ethics board approval in this instance is also received.
